Agios Pharmaceuticals, Inc.
AGIO
$34.41
-$1.09-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.04M | 36.50M | 32.87M | 31.31M | 29.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.04M | 36.50M | 32.87M | 31.31M | 29.40M |
| Cost of Revenue | 310.03M | 305.45M | 299.46M | 308.69M | 299.80M |
| Gross Profit | -273.00M | -268.95M | -266.59M | -277.39M | -270.40M |
| SG&A Expenses | 167.30M | 156.78M | 140.39M | 127.68M | 122.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 477.33M | 462.24M | 439.85M | 436.37M | 422.35M |
| Operating Income | -440.29M | -425.74M | -406.98M | -405.06M | -392.95M |
| Income Before Tax | 710.23M | 717.97M | 727.43M | -364.93M | -352.62M |
| Income Tax Expenses | 44.24M | 44.24M | 53.12M | -- | -- |
| Earnings from Continuing Operations | 665.99 | 673.73 | 674.31 | -364.93 | -352.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 665.99M | 673.73M | 674.31M | -364.93M | -352.62M |
| EBIT | -440.29M | -425.74M | -406.98M | -405.06M | -392.95M |
| EBITDA | -434.71M | -420.08M | -401.29M | -399.10M | -386.77M |
| EPS Basic | 11.71 | 11.82 | 11.79 | -6.49 | -6.31 |
| Normalized Basic EPS | -4.15 | -4.08 | -4.00 | -4.06 | -3.94 |
| EPS Diluted | 11.28 | 11.39 | 11.36 | -6.50 | -6.31 |
| Normalized Diluted EPS | -4.12 | -4.06 | -3.98 | -4.06 | -3.94 |
| Average Basic Shares Outstanding | 228.30M | 227.23M | 226.05M | 224.92M | 223.72M |
| Average Diluted Shares Outstanding | 229.80M | 228.72M | 227.55M | 224.92M | 223.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |